#Netherlands #Maastricht #CAAS vFFR #LIPSIA-STRATEGY #Pie Medical

Pie Medical Imaging's LIPSIA-STRATEGY Trial

The LIPSIA-STRATEGY trial conducted by Pie Medical Imaging has recently made headlines by demonstrating the non-inferiority of angiography-based Coronary Angiography Analysis System (CAAS vFFR) guided revascularization compared to the conventional guide-wire based FFR (Fractional Flow Reserve) revascularization. This groundbreaking study sheds light on a significant advancement in cardiovascular treatment options.

Overview of the LIPSIA-STRATEGY Trial

The LIPSIA-STRATEGY trial is a multicenter, randomized trial involving 1,053 patients suffering from intermediate coronary artery stenosis. The primary aim was to assess whether revascularization guided by CAAS vFFR correlates with clinical outcomes equivalent to those achieved with traditional pressure wire-based FFR procedures. Randomly assigned, patients underwent either the vFFR guided treatment or the conventional FFR method, with a focus on the occurrence of major adverse cardiovascular events (MACE) over the span of one year.

Led by medical expert Professor Holger Thiele from the Leipzig Heart Center, this pivotal study achieved its primary endpoint, confirming that the clinical results from the CAAS vFFR guided treatment are indeed comparable to those from the conventional method. Professor Thiele remarked, "Measuring FFR based on angiography is simpler and yields similar clinical outcomes. Thus, this should be the new standard for treating intermediate coronary artery stenosis."

Key Findings and Implications

The findings of the LIPSIA-STRATEGY trial provide robust evidence of the efficacy of CAAS vFFR in coronary revascularization. The trial validates earlier findings presented in the FAST III study, which also highlights comparable clinical outcomes for CAAS vFFR. These results indicate a clinically significant transition towards less invasive and quicker workflows, ultimately leading to decreased radiation exposure for both healthcare professionals and patients.

Bas Kuppens, CEO of Pie Medical Imaging, elaborated on the implications of the findings, stating, "LIPSIA-STRATEGY reinforces the insights gathered from the FAST III study, broadening the clinical evidence supporting CAAS vFFR. This cements our faith in physiologically guided angiography solutions. Alongside the less invasive approach and reduced procedure time, these findings signpost a future where physiological decision-making becomes more accessible throughout the percutaneous coronary intervention (PCI) process, right from diagnostic evaluation to post-procedure assessment."

About Pie Medical Imaging

Pie Medical Imaging stands at the forefront of advanced cardiovascular imaging analysis, quantification, and visualization. Based in Maastricht, Netherlands, the company plays a vital role in the global innovation and marketing of its CAAS and 3mensio product lines. With decades of expertise and a relentless commitment to innovation, Pie Medical Imaging empowers physicians, researchers, and industry partners in enhancing diagnostics, procedural planning, and image-guided interventions. Furthermore, the company adheres to stringent international quality regulations, ensuring reliability and clinical trust in its offerings.

As part of the Esaote Group, a leader in biomedical equipment, Pie Medical Imaging is steadfast in its mission to revolutionize cardiovascular care, reinforcing its position as a vital player in the healthcare technology landscape.

For more details, visit Pie Medical Imaging's website.